At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 43 enrolled
Drug / intervention
Extended Release Metadoxinedrug
Likely dose
Extended Release Metadoxine 1400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy Study of Metadoxine SR Formulation in ADHD Subjects
In Brief
A Phase 1 clinical trial evaluating Extended Release Metadoxine for Attention Deficit Hyperactivity Disorder. Completed, enrolled 43 participants across 1 site.
Detailed Summary
This clinical study is designed to evaluate the safety and tolerability of a single oral administration of a Metadoxine slow release formulation to subjects diagnosed as having ADHD. Study also assess cognitive effects of such drug administration.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention Deficit Hyperactivity Disorder
CountriesIsrael
Collaborators--
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2009
First PostedOct 2009
Primary CompletionOct 2010
TodayJul 2026
First PostedOct 14, 2009
Enrollment StartOct 1, 2009
Primary CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 16.7 years ago
Interventions
Extended Release Metadoxinedrug
one oral 1400mg dose (2 tablets)